Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
130 participants
OBSERVATIONAL
2021-08-16
2026-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Novel Therapies in ctDNA Positive GI Cancers
NCT05482516
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
NCT04842916
Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
NCT02450032
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
NCT06109805
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The targeted treatment will be given as per standard of care. Translational blood samples will be drawn pre-treatment, before the third cycle of chemotherapy, and hereafter corresponding to the planned imaging during treatment and follow up.
The total cell free DNA will be quantified in all samples. The samples will be analyzed for tumor specific mutations such as the KRAS, BRAF, and NRAS oncogenes, by ddPCR. Circulating tumor DNA will also be identified by hypermethylation markers, and a focused panel of next generation sequencing can be applied. The samples will also be analyzed for immune-related biomarkers.
The investigators expect to include up to 130 patients.
This is a purely observational translational study. Results will be analysed in relation to outcome data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of cancer of the gastrointestinal tract may be made by histo- or cyto-pathology, or by clinical and imaging criteria
* Planned for targeted treatment
* Age 18 years or older
* Able to understand written information
* Consent to samples for translational research
Exclusion Criteria
* Another concomitant cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Louise Bach Callesen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Louise B Callesen, MD
Role: PRINCIPAL_INVESTIGATOR
Experimental Clinical Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Oncology, Aarhus University Hospital
Aarhus N, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Louise B Callesen, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-10-72-7-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.